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Abstract
Background: Cardiovascular autonomic neuropathy (CAN) increases morbidity and mortality in diabetes through
association with a high risk of cardiac arrhythmias and sudden death, possibly related to silent myocardial ischemia.
During the sub-clinical stage, CAN can be detected through reduction in heart rate variability (HRV). The aim of our
study was to estimate if the time and frequency-domain analysis can be valuable for detecting CAN in young patients
with type 1 diabetes mellitus (T1DM).
Methods: For this case control study of evaluation of cardiovascular autonomic function the 15–25 years age group of
patients with duration of T1DM more than 9 years (n = 208, 89 males and 119 females) were selected. 67 patients
with confirmed CAN were assigned to the “case group” and 141 patients without CAN served as a control group,
the duration of T1DM was similar (15.07 ± 4.89 years vs.13.66 ± 4.02 years; p = 0.06) in both groups. Cardiovascular
autonomic reflex tests and time and frequency domains analysis of HRV were performed for all subjects.
Results: Time domain measures were significantly lower in CAN group compared with control (p < 0.05). R-R
max / R-R min ratio and coefficient of variation (CV) were the lowest during deep breathing among T1DM
patients with CAN. Receivers operating characteristic (ROC) curves were constructed to compare the accuracies
of the parameters of time-domain analysis for diagnosing CAN. We estimated a more reliable cut-off value of
parameters of time-domain. The CV values in supine position <1.65, reflected sensitivity 94.3%, specificity 91.5%.
The CV values during deep breathing <1.45 reflected sensitivity 97.3%, specificity 96.2%. The CV values in
standing position <1.50 reflected sensitivity 96.2%, specificity 93.0%. The most valuable CV was during deep
breathing (AUC 0.899). The results of frequency-domain (spectral analysis) analysis showed significant decrease in
LF power and LFPA, HF Power and HFPA, total power among subjects with CAN than compared with subjects
without CAN (p < 0.05).
Conclusions: Time and frequency domain analysis of HRV permits a more accurate evaluation of cardiovascular
autonomic function, providing more information about sympathetic and parasympathetic activity. The coefficient
of variation (time-domain analysis) especially during deep breathing could be valuable for detecting CAN.
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Background
Cardiovascular autonomic neuropathy (CAN) is one of
the most clinically significant and overlooked of all
serious complications of diabetes mellitus (DM) [1].
CAN occurs when peripheral autonomic fibres (sympa-
thetic and parasympathetic) of the cardiovascular system
are affected, resulting in abnormalities in heart rate (HR)
control and vascular dynamics [2, 3]. CAN is associated
with a high risk of cardiac arrhythmias and sudden
death, possibly related to silent myocardial ischemia, and
significantly increases morbidity and mortality risk in
diabetes [4]. CAN may have greater predictive power
than traditional risk factors for cardiovascular events [5],
increasing risk of premature death in type 1 diabetes
mellitus (T1DM) with CAN fourfold [6].
CAN might be subclinical for several years until the
patient develops resting tachycardia, exercise intoler-
ance, postural hypotension, cardiac dysfunction and
diabetic cardiomyopathy [2]. The time scale for CAN
progression from subclinical to clinical stage is un-
known. During the sub-clinical stage, CAN could be
detected through abnormalities (reduction) in heart
rate variability (HRV) [7–9]. Cardiovascular autonomic
reflex tests (CARTs) are simple non-invasive tests to
measure cardiac autonomic function based on the heart
rate (HR) and blood pressure response to certain
physiological manoeuvres. In healthy individuals, the
beat-to-beat variability with aspiration is predominantly
affected by the direct sympathetic and parasympathetic
activity [9]. CARTs are the gold standard in clinical
autonomic testing, they have good sensitivity, specifi-
city, and reproducibility and are non-invasive, safe,
well-standardized [10, 11].
Newer methods for detecting CAN are more sensitive,
and abnormalities in frequency and time domains of
HRV analysis may be detected before the development
of abnormalities in CARTs [12–14]. HRV can be
assessed either by calculation of indices based on statis-
tical analysis of R-R intervals (time-domain analysis) or
by spectral analysis (frequency-domain analysis) [10].
Power spectral analysis is a modern technology, which
uses a mathematical algorithm (fast Fourier transform)
to turn a complex biological signal, such as HRV (result
of the sympathovagal balance in the sinus node), into its
causing components, presenting them according to the
frequency with which they alter the HR [15]. The power
spectrum of HRV has been shown to consist of three
major peaks [2]: very low-frequency component is re-
lated to fluctuations in the vasomotor tonus linked to
thermoregulation and sweating (sympathetic control);
low-frequency component associated with the baroreflex
(sympathetic control with n. vagus modulation);
high-frequency component which is related to sinus
arrhythmia (parasympathetic control).
Studies have shown that HRV abnormalities can even
be present at the time of diabetes diagnosis [13]. Early
detection and good glycaemic control have been proven
to prevent or delay adverse outcomes associated with
diabetes complications [16, 17]. Therefore preventive
screening is required in order to identify CAN in its
earliest stages and particularly for those, who has dia-
betes from childhood. There is some evidence that pu-
berty is a threshold for the development of AN, because
changes during puberty may accelerate microvascular
complications of diabetes [18, 19].
The aim of our study was to estimate if the time and
frequency-domain analysis can be valuable for detecting
CAN in young patients with T1DM.
Methods
Study population
A case control study was conducted in a single research
centre as a part of joint Lithuanian – Swiss project
“Genetic Diabetes in Lithuania”. The principal aim of
the project was to screen for autoimmune antibodies
and in order to select patients for the searching mono-
genic diabetes and to compare the antibody positive with
the antibody negative population of the diabetes registry
(<25 years of age). The total project cohort consisted of
1209 subjects covering all paediatric patients (<18 years,
n = 860), and part of adult patients younger than 25 years
(n = 349) diagnosed with T1DM in Lithuania. All pa-
tients had a physician diagnosis of T1DM between
March 1990 and March 2015. In patients at the age less
than 15 years insulin-dependent diabetes was diagnosed
according to DIAMOND criteria [20]: diagnosis con-
firmed by physician, age at the onset less than 15 years,
the date of the onset coincide with the day of the first
insulin injection, the person is inhabitant of Lithuania.
In adult persons insulin-dependent diabetes was diag-
nosed according to criteria [21]: diagnosis confirmed by
physician, age at the onset 15–39 years, the date of the
onset coincide with the day of the first insulin injection,
the person is inhabitant of Lithuania, ketones present in
urine on the time of diagnosis of diabetes. Patients were
identified from Lithuanian national diabetes data base
and invited to participate in the study on their visit to
the family doctor and/or endocrinologist, a paediatric
endocrinologist, meetings of diabetes societies, as well as
by post, e-mails and phone calls.
For this case control study of evaluation of cardiovascu-
lar autonomic function we selected the 15–25 years age
group of patients with duration of T1DMmore than 9 years
(n = 208, 89 males and 119 females). Sixty-seven patients
with confirmed CAN were assigned to the case group and
141 patients without CAN served as a control group in this
analysis, the duration of T1DM was similar (15.07 ±
4.89 years vs.13.66 ± 4.02 years; p = 0.06) in both groups.
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The study was approved by local ethical committee
(No. BE–2-5/2013) and written informed consent was
obtained from all study participants and their parents or
official care-givers. The investigation was carried out in
accordance with the Declaration of Helsinki.
Materials
An electrocardiogram (ECG) of CARTs was recorded
using AT-101 CARDIOVIT device (Schiller, Swiss, Soft-
ware analysis SEMA-200). Before assessment, partici-
pants avoided alcohol, smoking, coffee and were at least
2 h after a light meal. The absence of marked hypergly-
caemia or hypoglycaemia was confirmed measuring ca-
pillary blood glucose. Participants were examined in the
supine position after 10–15 min of rest in the morning
(from 8:00 to 11:00 a.m.).
A baseline recording was obtained during normal
breathing in a quiet room.
Deep breathing test: ECG recording was obtained over
2 min. during deep breathing at a frequency of 6 breaths
per min. (5 s in and 5 s out). The expiration vs. inspir-
ation ratio (E vs. I ratio) was determined by the ratio be-
tween the longest and shortest R-R intervals obtained
during the expiration and inspiration cycles, respectively,
and the highest E:I ratio was considered.
Heart rate response to active standing (orthostatic):
After lying in the supine position for at least 10 min.,
the subject stand up quickly. The 30 vs. 15 ratios were
determined by the ratio between the longest and short-
est RR intervals (maximum bradycardia / maximum
tachycardia).
Orthostatic hypotension test: After at least 10 min. of
supine rest, the blood pressure was measured at baseline
and after 3 min. of standing. Drops in the systolic blood
pressure (SBP) higher or equal to 20 mmHg or in the
diastolic blood pressure (DBP) higher or equal to
10 mmHg were considered abnormal.
Diastolic blood pressure response to isometric exercise
(hand grip using dynamometer): The subject squeezes a
handgrip dynamometer to establish a maximum. Grip is
then squeezed at 30% maximum for 5 min. The abnor-
mal response for diastolic blood pressure was a rise of
less than 10 mmHg in the other arm [22].
CAN was diagnosed based on at least two abnormal
cardiovascular autonomic reflex test results.
ECG of time and frequency-domain tests was recorded
with Neuropack MEB-9400 device (NIHON KOHDEN,
Japan) with special software QP-948 BK for exploration
of autonomic nervous system (for analysis of HRV indi-
ces). The device takes into account the normal hearts
beats, derives the statistical parameters of the normal R-
R intervals (NN) and computes time and frequency
domain HRV indices. To avoid noise and artefact, the
participants and the electrode junction box were placed
more than 1 m away from the system. The participants
were instructed to remain at rest, to avoid movements
and conversations during data collection. Three surface
electrodes were placed on the chest to obtain an electro-
cardiogram tracing. We have possibility using software
QP-948 BK to eliminate ectopic beats, noises and arte-
facts after visual detection. Short-term recordings (up to
5 min. in the resting state and up to 2 min. during deep
breathing and standing) yield up to two peaks in low
and high frequency ranges.
Time-domain parameters were analysed: the ratio of
maximum R-R interval / minimum R-R interval (R-R
max / R-R min), the standard deviation of R-R interval
(SD), the percentage of differences between adjacent RR
intervals > 50 ms (pNN50) and coefficient of variation of
R-R interval (CV) (CV = SD/mean R-R interval*100).
Frequency-domain parameters were analysed: LF range
(0.04–0.15-Hz), LF Power - power of the highest peak in
the lower frequency range, LFPA - total power of the
lower frequency range; HF range (0.15–0.4 Hz), HF
Power - power of the highest peak in the higher frequency
range, HFPA - total power of the higher frequency range;
LF-to-HF ratio; LFPA-to-HFPA ratio; and total power
(TP) of the spectrum (0.003–0.4 Hz). The spectral analysis
was calculated using a mathematical Fast Fourier Trans-
form algorithm.
Standardised questionnaires were completed to obtain
information on demographic data, clinical events, medi-
cations and life style.
Laboratory tests: The following laboratory tests were
performed: glycated haemoglobin (HbA1c), total choles-
terol, high density lipoprotein (HDL), low density lipo-
protein (LDL), triglycerides (TG).
Statistical data analysis
The statistical analysis was conducted using the SPSS 22.0
statistics software package. The mean, standard deviation
(SD) and the 95% confidence interval (CI) are indicated
for quantitative variables; and value rates as well as relative
rates in percent are indicated for qualitative variables.
In order to determine the sample size, the force β = 0.8
and the probability value α =0.05 were chosen.
The Student t test was used to check the average
equality hypothesis in case of normal data distribution
and the Mann-Whitney test in case of non-normal data
distribution.
The independence of qualitative variables was tested
using the chi-square χ2 test; and if the number of moni-
tored patients was low, the Fisher exact criterion was
applied.
The areas under the Receiver Operating Characteris-
tics (ROC) curves were calculated. Possible dependent
variable values and their specificity and sensitivity were
estimated.
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The significance level 0.05 was chosen to test statis-
tical hypotheses.
Results
The 208 patients with T1DM (89 males and 119 females)
were included in the study. The characteristics of pa-
tients are summarized according CAN in Table 1. There
were no significant differences in mean diabetes duration
and gender distribution among study subjects with and
without CAN (cases vs. controls). SBP and HDL were
similar among groups (p > 0.05). However, DBP and HR
were significantly higher among case group compared
with control group. T1DM patients with CAN (cases)
were more likely to have a worse metabolic profile:
higher HbA1c (p = 0.002), total cholesterol (p < 0.001),
LDL (p = 0.003), TG (p = 0.005).
CARTs measures were analyzed and compared be-
tween young T1DM patients with CAN and without
CAN. Results of analysis are presented in Table 2. All
CARTs measures were significantly lower in case group
than in control (p < 0.05).
We analysed if gender influenced the abnormal
changes of CARTs among type1 diabetic patients with
CAN (Table 3). We have found no significant differences
in abnormal CARTs measures between males and fe-
males with T1DM and CAN (p > 0.05).
Time domain measures of HRV were computed for
R-R intervals in supine position, deep breathing and
standing position both in case and control groups. The
results of time domain analysis are summarized in
Table 4. All measures were significantly lower in case
group when compared with control group (p < 0.05). R-
R max / R-R min ratio and CV were the lowest during
deep breathing among T1DM patients with CAN. How-
ever, T1DM patients without CAN showed the lowest
R-R max / R-R min ratio and CV in supine position.
The results of frequency-domain (spectral analysis)
analysis are presented in Table 5. LF power and LFPA
(showing sympathetic control with n. vagus modulation)
Table 1 Characteristics of type 1 diabetes according to the
presence of CAN






Gender (M/F) 29/38 60/81 0.23
Age (years) 20.04 ± 4.91 18.82 ± 3.86 <0.01
Diabetes duration (years) 15.07 ± 4.89 13.66 ± 4.02 0.06
SBP (mmHg) 124.58 ± 10.12 118.12 ± 8.62 0.07
DBP (mmHg) 77.53 ± 8.72 74.58 ± 6.23 <0.01
HR (bpm) 81.37 ± 9.93 73.70 ± 8.65 <0.01
HbA1c (%) 9.46 ± 1.63 8.77 ± 1.80 0.002
Total cholesterol
(mmol/l)
5.64 ± 1.23 4.88 ± 1.03 <0.001
HDL (mmol/l) 1.26 ± 0.37 1.30 ± .0.25 0.16
LDL (mmol/l) 3.11 ± 0.89 2.79 ± 0.78 0.003
Triglyceride (mmol/l) 1.24 ± 0.65 1.06 ± 0.42 0.005
Note: Data are means (standard deviation) unless otherwise indicated
Table 2 Comparison of CARTs results between case and
control groups
Mean −95 CI +95 CI
R-R index of deep breathing (E:I)
Case group 1.13 1.09 1.17
Control group 1.34 1.31 1.36
p <0.001
R-R index of active standing (30:15)
Case group 1.14 1.10 1.17
Control group 1.26 1.23 1.28
p <0.001
SBP Δ (orthostaic hypotension test)
Case group −6.01 −7.55 −4.44
Control group 3.63 1.16 5.10
p 0.005
DBP Δ (hand grip using dynamometer)
Case group 8.30 7.64 8.36
Control group 16.47 15.56 16.51
p 0.002
Note: ±95 proc. CI confidence intervals
Table 3 Statistical indicators of abnormal changes of CARTs
according to gender among type 1 diabetic youth with CAN
Mean −95 CI +95 CI
Index of deep breathing (E:I) ≤1.1
Male 1.01 1.01 1.02
Female 1.02 1.01 1.03
p 0.82
Index of orthostatic (30:15) ≤1.1
Male 1.04 1.02 1.06
Female 1.04 1.03 1.06
p 0.76
SBP Δ (orthostatic hypotension) ≤ −20 mmHg
Male −22.00 −27.55 −16.44
Female −23.63 −28.16 −19.10
p 0.84
DBP Δ (hand grip)≤ −10 mmHg
Male −12.30 −14.65 −9.96
Female −13.47 −15.76 −11.18
p 0.43
Note: ±95 proc. CI confidence intervals
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were significantly lower among T1DM patients with
CAN (cases) than compared with T1DM patients with-
out CAN (controls) (p < 0.05). Also HF Power and HFPA
(showing parasympathetic control only) were signifi-
cantly lower among case group than compared with
control group (p < 0.05). HFPA was lower than LFPA
among both groups. Total power (corresponds to the
sum of all spectral bands) was significantly lower
among subjects with CAN than in subjects without
CAN (p < 0.05). There were no significant differences
in LF/HF and LFPA/HFPA (reflects global sympathetic
- parasympathetic balance) among groups (p > 0.05).
Receivers operating characteristic (ROC) curves were
constructed to compare the accuracies of the parameters
of time-domain analysis for diagnosing CAN (Table 6,
Fig. 1). We estimated a more reliable cut-off value of
parameters of time-domain. The CV values in supine
position <1.65 reflected sensitivity 94.3%, specificity
91.5%. The CV values during deep breathing <1.45
reflected sensitivity 97.3%, specificity 96.2%. The CV
values in standing position <1.50 reflected sensitivity
96.2%, specificity 93.0%. So the most valuable CV was
during deep breathing (AUC 0.899).
Discussion
The results of our study showed the reduction of overall
HRV in young T1DM patients with confirmed CAN,
when compared with patients with the similar duration of
disease and glycaemic control, but without CAN. HRV in
deep breathing under parasympathetic control was most
often impaired in CAN. This study has demonstrated the
importance of the CV for diagnosing CAN. Spectral ana-
lysis confirmed the significant decreases in parameters
of HF and LF ranges. Our study results confirmed that a
decrease in HRV is an early sign of CAN.
The reported prevalence of CAN varies, depending on
the type and number of tests performed, different cri-
teria used to diagnosed autonomic dysfunction and also
the patient cohort studied [23]. Ziegler et al., evaluated a
large cohort of patients (647 T1DM and 524 T2DM)
and found that 25.3% of patients with T1DM and 34.3%
of patients with T2DM had abnormal findings in more
than two of six autonomic function tests [24]. CAN
could be detected in about 7% of T1DM at the time of
initial diagnosis, and it is estimated that the risk for
developing CAN increases annually by approximately 6%
[25]. The improvement of glycaemic control could
reduce the prevalence and the progression of CAN.
Autonomic failure was confirmed in 12.3% of people
with T1DM in French study in 2010 [26]. Moreover,
there are evidences that autonomic dysfunction may be
accelerated by puberty suggest the screening of adoles-
cents and young adults for CAN [27].
HbA1c, hypertension, age, hypertrigliceridaemia, dysli-
pidaemia, gender (female), diabetic symmetric peripheral
neuropathy, albuminuria, retinopathy, and exposure to
hyperglycemias are risk factors for developing CAN
among T1DM [28]. Subjects with confirmed CAN had
significant higher DBP and worse lipid profile (p < 0.05)
in our study. The association of CAN with other diabetes
microangiopathic complications should lead to consider
CAN as an indicator of them [26]. Antony et al. examined
the relationship between 24-h blood pressure measure-
ments, urinary albumin excretion rates, and autonomic
neuropathy in adolescents with T1DM. They concluded
that higher 24-h BP values and evidence of subclinical
signs of autonomic neuropathy are present before persist-
ent microalbuminuria develops and may have important
implications for timing the introduction of early treat-
ments designed to prevent or retard the microvascular
complications in T1DM adolescents [29].
Table 4 Differences of HRV parameters (time-domain method)
between type 1 diabetic patients with and without CAN
Variable T1DM with CAN T1DM without CAN p
Supine position
R-R max / R-R min 1.12 ± 0.07 1.28 ± 0.18 <0.001
SDNN (ms) 16.69 ± 8.50 45.16 ± 25.92 <0.001
pNN50 (%) 0.95 ± 0.65 20.10 ± 2.56 <0.001
CV (%) 2.27 ± 1.07 4.63 ± 2.38 <0.0001
Deep breathing
R-R max / R-R min 1.1 ± 0.05 1.36 ± 0.24 <0.001
SDNN (ms) 31.87 ± 13.68 41.13 ± 16.24 0.02
pNN50 (%) 1.60 ± 0.87 26.63 ± 2.38 <0.001
CV (%) 2.09 ± 0.98 6.72 ± 4.27 <0.0001
Standing position
R-R max / R-R min 1.14 ± 0.18 1.38 ± 0.27 <0.001
SDNN (ms) 24.85 ± 5.19 56.12 ± 4.44 <0.001
pNN50 (%) 0.71 ± 0.50 12.18 ± 6.59 <0.001
CV (%) 2.59 ± 1.65 6.37 ± 4.05 <0.0001
Note: Data are means (standard deviation)
Table 5 Differences of HRV parameters (frequency-domain
method) between type 1 diabetic patients with and without CAN
Variable T1DM with CAN T1DM without CAN p
Spectral analysis
LF Power (ms2) 2.26 ± 0.28 5.79 ± 1.24 <0.01
LFPA (ms2) 10.13 ± 1.28 26.78 ± 4.78 <0.001
HF Power (ms2) 1.47 ± 0.22 3.97 ± 0.64 <0.001
HFPA (ms2) 7.39 ± 1.11 20.07 ± 2.83 <0.0001
LF/HF (%) 32.39 ± 1.95 37.64 ± 2.69 0.11
LFPA/HFPA (%) 175.01 ± 26.30 142.25 ± 14.49 0.30
T Power (ms2) 29.36 ± 3.19 70.48 ± 9.17 <0.001
Note: Data are means (standard deviation)
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It is important to diagnose CAN in its subclinical (early)
stage. Lack of HRV during deep breathing or exercise is a
sign of autonomic nerve impairment. Reduced HRV is the
earliest indicator of CAN [30]. Resting HR of 100–
130 bpm are a manifestation of later stages of the disease
and reflect the relative increase in the sympathetic tone
associated with n. vagus impairment [31]. Later develops
combined parasympathetic and sympathetic damage, HR
returns toward normal but still remains elevated [10]. A
fixed HR that is unresponsive to moderate exercise, stress,
or sleep indicates almost complete cardiac denervation
[31]. In our study young T1DM patients with CAN had
significant higher resting HR when compared with control
group (p < 0.05). Vanderlei et al. have tried to verify pos-
sible associations between HRV indices and physical activ-
ity, body composition, and metabolic and cardiovascular
parameters in individuals with T1DM. They have found
that for young patients with T1DM, increases in at-rest
HR values are associated with reduced parasympathetic
activity and global HRV, whereas higher waist-to-hip ratio
values are related to lower parasympathetic activity, both
independent of age and gender [32].
CAN is still widely under-diagnosed, despite its high
prevalence and impact on morbidity and mortality.
Despite the existing guidelines for the diagnosis of CAN,
there is no widespread standardized method to CAN
testing [33]. Autonomic symptoms are nonspecific and
do not permit diagnosis of CAN. CARTs are the gold
standard in clinical autonomic testing [10]. The most
widely used tests assessing cardiac parasympathetic
function are based on HR response to deep breathing
(expiration/inspiration ratio), active standing (max-
imum/minimum 30:15 ratio) and a Valsalva manoeuvre.
HR to deep breathing has the greatest specificity (80%).
However, CARTs have some contraindications and they
require a very good cooperation of patients. A Valsalva
manoeuvre must not be performed in patients with
proliferative retinopathy. That’s why we didn’t included
it in our study. The sympathetic function is assessed by
measuring the blood pressure response to orthostatic
change, hand grip using dynamometer and a Valsalva
manoeuvre. In our study all CARTs measures of T1DM
young patients with CAN were significantly lower than
those without CAN (p < 0.05).
Table 6 Summary ROC plot of sensitivity versus specificity of the coefficients of variation for CAN
Variable Value AUC ±95% CI Sn (%) Sp (%)
CV1 in supine position <1.65 0.890 ± 0.033 0.825–0.955 94.3 91.5
CV2 in deep breathing <1.45 0.899 ± 0.035 0.831–0.967 97.3 96.2
CV3 in standing position <1.50 0.862 ± 0.039 0.785–0.939 96.2 93.0
Note: AUC area under the curve, Sn sensitivity, Sp specificity
Fig. 1 ROC curve and corresponding AUC of the CV in distinguishing cases from controls are presented. Note: CV 1 – in supine position,
CV 2 – during deep breathing, CV 3 – in standing position
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New methods for detecting CAN offer to assess HRV
either by calculation of indices based on statistical ana-
lysis of R-R intervals or by spectral analysis [10]. They
are easily performed and do not require cooperation of
patients. In SEARCH CVD study HRV parameters were
measured in 354 young patients with T1DM (mean age
18.8 years, diabetes duration 9.8 years, and mean A1C
8.9%) and 176 young persons without diabetes (mean
age 19.2 years). Youth with T1DM had reduced overall
HRV and markers of parasympathetic loss (reduced HF
power) with sympathetic override (increased LF power)
when compared with control subjects. So, a conclusion
was that diabetic youth with signs of early CAN have
reduced overall HRV and parasympathetic loss with
sympathetic override [34]. Jovarka et al. have tested the
hypothesis that cardiovascular regulation is abnormal in
young patients with T1DM. In young patients with
T1DM significant reduction of spectral power in HF
band of the HRV was found, whereas no significant
difference between DM group and control group was
observed in LF band of blood pressure variability. They
suggested that abnormalities in cardiac parasympathetic
regulation precede impairment of blood vessels sympa-
thetic control in young diabetics [35]. The measures of
time domain analysis of our study were significantly
lower among T1DM youth with CAN when compared
with control group (p < 0.05). Also R-R max / R-R min
ratio and CV were the lowest during deep breathing
among T1DM youth with CAN (showing decrease in
parasympathetic activity). We analysed sensitivity and
specificity of the coefficient of variation (parameter of
time-domain analysis) for diagnosing CAN and have
found that the most valuable CV was during deep
breathing (values <1.45 reflected sensitivity 97.3%, speci-
ficity 96.2%). The results of spectral analysis of our study
confirmed the significant decrease in HF, LF and total
power (showing decrease in parasympathetic and sympa-
thetic activity) among patients with CAN. Also we have
found that LFPA and HFPA were significantly lower
among cases than compared with control group, but
these indices are not so valuable from mathematical
point of view. Power Spectral Analysis and HRV have
been employed in trials for the detection of autonomic
neuropathy in patients with Charcot’s disease. Similarly
to Charcot’s arthropathy, patients with recurrent vascu-
lar neuropathic ulcers appear to share analogous cardiac
autonomic dysfunction [9]. Hikita et al. [36] demon-
strated that HRV is reduced in diabetic patients with si-
lent ischemia when compared with non-diabetic patients
with silent or painful ischemia in 24-h ambulatory elec-
trocardiographic recordings. Katz et al. showed that a
simple test that measured 1-min HRV during deep
breathing was a good predictor of all-cause mortality for
185 patients (17.8% with diabetes) after a first MI [10].
Various studies are trying to create more useful tool
for the early detection of CAN in patients with T1DM
[37, 38]. Jovarka et al. [38] have analysed if a new HRV
complexity measure, the Point Correlation Dimension
(PD2i), could provide diagnostic information regarding
early subclinical autonomic dysfunction in T1DM. The
R-R intervals were measured over 1 h with a telemetric
ECG system. They have found that PD2i was able to de-
tect ANS dysfunction with p = 0.0006, similar to the best
discriminating MSE scale, with p = 0.0002.
So, the significance of CAN has not been fully appreci-
ated and remains among the least understood and least
frequently diagnosed diabetes complications, despite its
significant negative impact on survival and quality of life
[2]. According ADA recommendations [39], diagnostic
tests of CAN should be performed for T1DM: 5 years
after the diagnosis; before planning a program of
moderate-to-high-intensity physical exercise; with a
history of poor glycaemic control, high cardiovascular
risk and microangiopathic complications.
One of the weaknesses of our case control study is a
narrow range of T1DM duration (more than 9 years).
We intend to evaluate CAN among T1DM with disease
duration more than 5 years or even from the diabetes
onset. The other weakness is that HRV was evaluated
from a short length of recording (5 min.). Another weak
point - we had only one HbA1c measurement not reflect-
ing longstanding glycaemic control. The major strength of
our study is the young T1DM population without con-
comitant medications and comorbidities interfering re-
sults of tests, homogeneous according diabetes duration.
The study used various parameters of time and frequency
domains analysis for the analysis of HRV.
Conclusions
Time and frequency domain analysis of HRV permits a
more accurate evaluation of cardiovascular autonomic
function, providing more information about sympathetic
and parasympathetic activity. The coefficient of variation
(time-domain analysis) especially during deep breathing
could be valuable for detecting CAN.
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